In Clincierge’s continued effort to support patient engagement, diversity, and inclusion in clinical research, we are proud to again support CISCRP’s Patient Diversity Campaign to raise awareness of clinical research opportunities among minority urban communities in cities across the United States.
CISCRP is The Center for Information and Study on Clinical Research Participation. Their mission is to inform the public about the clinical research process while increasing awareness and understanding of clinical trials.
View the campaign and full-page educational spread here.
We collaborated with CISCRP to sponsor a full-page educational spread in five print and digital newspaper publications. The campaign reached over 3 million diverse individuals across Black, African American, Hispanic, and Latino communities. The advertisement highlighted the importance of diversity among participants in clinical studies to find effective medications for all populations. It was included in the following publications:
- Michigan Chronicle – Detroit, Michigan
- Chicago Citizen – Chicago, Illinois
- La Opinion – Los Angeles, California
- The Atlanta Voice – Atlanta, GA
- Philly Tribune – Philadelphia, PA
This information was also distributed digitally in the following markets:
- The Atlanta Tribune – Atlanta, Georgia
- Atlanta Daily World – Atlanta, Georgia
- New Pittsburgh Courier – Pittsburgh, Pennsylvania
- Chicago Defender – Chicago, Illinois
Increasing patient diversity in clinical trials continues to be an ongoing effort across our industry. Each study stakeholder is responsible for ensuring safe treatment for participants of all ethnic backgrounds throughout the trial process. Clincierge aligns our services to support the varying needs of diverse populations.
For us, this commitment to diversity begins at home. Clincierge fosters diversity, equity, and inclusion in all aspects of our company culture. Our internal Diversity, Equity, and Inclusion Committee continues to create education and celebration opportunities.
Read more about our continued support of CISCRP and commitment to clinical trial diversity in 2023.
